Related Experiment Video

Updated: Jan 7, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K

Biophysical Characterization of an Engineered CD80 Variant for CTLA-4 Blockade in Cancer Immunotherapy

Zahra Hajihassan1, Amir Hossein Mosayebi2, Ramezan Ali Taheri3

  • 1School of Life Science Engineering, College of Interdisciplinary Science and Technology, University of Tehran, Tehran, Iran. hajihasan@ut.ac.ir.

The Protein Journal
|December 30, 2025
PubMed
Summary

No abstract available in PubMed .

Keywords:
Cancer immunotherapyImmune checkpoint inhibitorMutant CD80

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.8K

Related Concept Videos